-=Teva Pharma (TEVA) reported earnings on Wed 27 Oct 21 (b/o)

 

Teva Pharma misses by $0.06, misses on revs; reaffirms FY21 EPS guidance, revs guidance

• Reports Q3 (Sep) earnings of $0.59 per share, $0.06 worse than the S&P Capital IQ Consensus of $0.65; revenues fell 2.8% year/year to $3.89 bln vs the $4.05 bln S&P Capital IQ Consensus.
• Co reaffirms guidance for FY21, sees EPS of $2.50-2.70 vs. $2.60 S&P Capital IQ Consensus; sees FY21 revs of $16.0-16.4 bln vs. $16.35 bln S&P Capital IQ Consensus.